王朝鐘黃惠珮WANG, CHAU-JONGHUANG, HUI-PEI張心綿ZHANG, XIN-MIANXIN-MIANZHANG醫學研究所碩士班2026-10-292029-07-2220242024-07-22https://handle.ncl.edu.tw/11296/p26upkhttps://scholars.csmu.edu.tw/handle/123456789/36713糖尿病腎病變 (DN) 是糖尿病的一種併發症。研究指出,胰島素阻抗促使腎臟醣質新生的增加,加劇糖尿病患者的高血糖和腎臟損傷。褪黑激素-Melatonin (MT) 是調節日夜的賀爾蒙,主要有抗發炎、抗氧化、調節生理時鐘等功能。研究指出,MT可以抑制inflammatory cytokines、Apoptosis related protein、fibrogenic cytokines等,減少發炎、Podocyte loss、蛋白尿的產生,對於預防及治療DN有很大的潛力。近期研究表明,糖尿病患者腎臟醣質新生的增加會促進DN的產生。因此,本實驗動機擬觀察MT是否能改善高脂飲食糖尿病的醣質新生作用及腎臟損傷。實驗方式:使用C57BL/6J-Wild type及ApoE-/-的8週齡mice,總共飼養8 week,分成WT組、STZ組、HFD + STZ組、MT + HFD + STZ組。入室第2週後,施打STZ-55mg/kg 連續5天,並在10天後去監測老鼠血糖 (>200 mg/dL) 是否有誘導成DM,進一步餵食8 weeks/day的HFD飼料+管灌MT,每週/次監測血糖及體重。並於第8週進行犧牲,檢測血液生化數值及腎臟切片染色。結果顯示,誘導第二型糖尿病小鼠經過 MT處理過後,對於體重有著顯著的回復,血糖與糖化血色素數值也具備著統計意義的下降。MT的治療降低了因高脂飲食餵食而增加的腎功能指標( CRE 及BUN),與肝功能指標(GOT及GPT)。血脂方面,盡管施予MT後可以降低低密度膽固醇及總膽固醇,但對於三酸甘油脂及高密度膽固醇並沒有影響。在腎組織染色的結果中,經過 MT處理的組別腎小球的PAS陽性區域與腎間質基質增生比例,相比未經過藥物處理的組別有顯著的改善。從IHC的結果發現,MT的治療明顯地降低了發炎及促發炎相關蛋白:NF-κB、NLRP3、Caspase 1、IL-1β等蛋白的表達。在氧化壓力層面,MT的處理調降了DNA損傷相關蛋白8-OHdG的表達,並且在MT組顯著上調了抗氧化蛋白Nrf2的表現。腎醣質新生相關結果中發現,MT顯著的調降了醣質新生相關蛋白PEPCK、G6Pase兩個不可逆酵素的表達,儘管對於MT的作用機轉仍需探明。綜合上述結果,MT的治療可以藉由降低腎臟發炎、調降氧化壓力與抑制腎醣質新生作用來預防及治療糖尿病的慢性腎臟病,延緩糖尿病腎病變的發生。Diabetic nephropathy (DN) is a complication of diabetes mellitus. Research have shown that insulin resistance leads to increased renal gluconeogenesis, exacerbating hyperglycemia and kidney damage in diabetic patients. Melatonin (MT), a hormone that regulates circadian rhythms, exhibits anti-inflammatory, antioxidant, and circadian rhythm-regulating functions. Studies suggest that MT can inhibit inflammatory cytokines, apoptosis-related proteins, and fibrogenic cytokines, thereby reducing inflammation, podocyte loss, and proteinuria, demonstrating significant potential in the prevention and treatment of DN. Recent studies have suggested that increased renal gluconeogenesis in diabetic patients may contribute to the progression of DN. Therefore, this study aims to observe whether MT can improve gluconeogenesis and kidney damage in high-fat diet-induced diabetic mice. Eight-week-old C57BL/6J-Wild type and ApoE-/- mice were used, with a total feeding period of eight weeks. The mice were divided into the following groups: WT group, STZ group, HFD + STZ group, and MT + HFD + STZ group. Starting from the second week after the mice were brought into the laboratory, they were injected with STZ at 55 mg/kg for five consecutive days. After ten days later, blood glucose levels were monitored to confirm whether diabetes was induced (>200 mg/dL). The mice were then fed an HFD diet along with MT administration via gavage for eight weeks. Blood glucose levels and body weight were monitored weekly. At the end of the eighth week, the mice were sacrificed, and biochemical values in the blood and renal tissue staining were examined. In MT-treated mice, significant recovery in body weight was observed in type 2 diabetic mice. Besides, blood glucose and glycated hemoglobin levels showed statistically significant decreases. MT treatment reduced elevated renal function indicators (CRE and BUN) and liver enzymes (GOT and GPT) due to HFD feeding. In terms of blood lipids, MT administration reduced low-density lipoprotein cholesterol (LDL-C) and total cholesterol, but had no effect on triglycerides or high-density lipoprotein cholesterol (HDL-C). In renal tissue staining, the MT-treated groups showed significant improvement in glomerular PAS-positive areas and interstitial matrix proliferation compared to untreated groups. Immunohistochemistry (IHC) results indicated that MT treatment significantly reduced the expression of inflammatory and pro-inflammatory proteins: NF-κB, NLRP3, Caspase 1, IL-1β. At the oxidative stress level, MT treatment reduced the expression of the DNA damage-related protein 8-OHdG and significantly upregulated the expression of the antioxidant protein Nrf2 in the MT group. In terms of renal gluconeogenesis, MT significantly downregulated the expression of two key irreversible enzymes, PEPCK and G6Pase, associated with gluconeogenesis. Although the mechanism of MT's action needs further investigation, these results suggest that MT treatment may prevent and treat chronic kidney disease in diabetes by reducing renal inflammation, lowering oxidative stress, and inhibiting renal gluconeogenesis, thereby delaying the onset of diabetic nephropathy.糖尿病腎病變鏈脲佐菌素醣質新生褪黑激素Diabetic nephropathystreptozotocingluconeogenesismelatonin褪黑激素抑制鏈脲佐菌素誘導高脂飲食糖尿病性 apoE 缺陷小鼠之腎糖新生導致腎病變作用thesis